Peptide And Anticoagulant Drugs Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 3.30 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Peptide And Anticoagulant Drugs Market Analysis
The peptide and anticoagulant drugs market is projected to register a CAGR of 3.3% during the forecast period.
COVID-19 had a substantial impact on the market's growth initially. For instance, according to an article published by Frontiers in May 2022, several peptide-based vaccine candidates and drug candidates were proposed during the pandemic, which positively affected the treatment of COVID-19 infections. Thus, the pandemic had a significant impact on the market's growth. However, as the pandemic has subsided, the market is expected to have stable growth during the forecast period.
Factors such as the increasing prevalence of cancer and metabolic disorders, rising investments in the R&D of novel drugs, and technological advancements in drug development are expected to enhance the market's growth.
The rising prevalence of cancer and other metabolic disorders is a major factor driving the market's growth. For instance, as per the report published by the Chinese Medical Journal in March 2022, China is experiencing a greater incidence of cancers. In 2022, there were approximately 4,820,000 new cancer cases in China, the most common being lung cancer.
According to the data published by National Cancer Center Japan in June 2022, an estimated 1,019,000 new cases of cancer were expected in Japan in 2022, out of which 158,200 new cases of colon/rectum cancer, 132,100 cases of stomach cancer, 128,800 cases of lung/trachea cancer, 96,400 cases of prostate cancer, and 95,000 cases of breast cancer were expected. Thus, the greater incidence of cancers has increased the demand for various peptide drugs to treat these diseases.
The rising R&D for novel drugs is also expected to boost market growth. For instance, according to the 2021 annual report of Pfizer Inc., the company invested USD 13,829 million in FY 2021, which increased heavily compared to USD 9,343 million in the previous year. As per a press release published in April 2022 by Biocon Biologics Limited, a subsidiary of biopharmaceutical market player Biocon, expects its R&D investment to increase heavily by 10-15% in FY 2023, as the company is advancing its pipeline of novel drugs to drive future growth.
The rising developments by major market players are also expected to enhance market growth. For instance, in June 2021, the Janssen Pharmaceutical Companies of Johnson & Johnson announced that the US FDA approved two pediatric indications for XARELTO (rivaroxaban), an oral anticoagulant drug. The new indications are for treating venous thromboembolism (VTE, or blood clots) and reducing the risk of recurrent VTE in patients from birth to less than 18 years after at least five days of initial parenteral (injected or intravenous) anticoagulant treatment.
Factors such as the increasing prevalence of cancer and metabolic disorders, rising investments in the R&D of novel drugs, and technological advancements in drug development are expected to enhance the market's growth. However, the high cost of developing drugs and stringent government regulations are expected to hinder this growth.
Peptide And Anticoagulant Drugs Market Trends
Cancer Segment is Expected to Hold a Significant Market Share Over the Forecast Period
Cancer is a disease in which some of the body's cells grow uncontrollably and spread to other body parts. The increasing prevalence of cancer worldwide and the rising R&D for better oncology drugs are the major factors expected to boost segmental growth during the forecast period.
For instance, according to a report published by PubMed Central in March 2022, 274,488 new cancer cases and 81,277 cancer deaths were expected in South Korea in 2022. The most common cancer types were expected to be thyroid cancer, followed by lung cancer, colon and rectum cancer, breast cancer, and stomach cancer. These five types of cancer are expected to represent half of the overall burden of cancer in South Korea. The most common type of cancer leading to death is expected to be lung cancer, followed by liver, colorectal, pancreatic, and gallbladder cancers. Thus, the rising prevalence of cancer is expected to boost the usage of peptide drugs.
According to the bi-annual report published by the Indian Council of Medical Research (ICMR) in December 2022, the national average of cancer cases in 2022 in India was 100.4 per 100,000, with a large number of women (an estimated 105.4 per 100,000) being diagnosed with breast cancer. The source also stated an estimated 182,000 people are living with breast cancer in India, which is expected to reach 250,000 by 2030. Thus, due to the country's high burden of breast cancer, the demand for peptide drugs is expected to increase, which will drive the growth of the studied market.
According to the data published by the NIH in May 2022, research funding for cancer in the United States was expected to increase from USD 7,362 million in 2021 to USD 7,644 million in 2022. Thus, the rising R&D expenses for cancer are expected to boost segmental growth.
Hence, factors such as the rising prevalence of cancer and the growing R&D expenses for cancer are expected to drive the segment during the forecast period.
North America is Expected to Hold a Significant Market Share Over the Forecast Period
North America is expected to hold a significant share of the peptide and anticoagulant drugs market throughout the forecast period due to the increasing necessity of drugs for cancer, increasing prevalence of cardiovascular disorders and other diseases, and high demand for peptide and anticoagulant drugs. The United States holds the largest market share in the North American region due to factors such as the increasing burden of cancer and the increasing prevalence of cardiovascular disorders, which is anticipated to stimulate the demand for peptide and anticoagulant drugs.
The rising prevalence of various cancer in the region is stimulating the market's growth. For instance, as per the Canada Cancer Society's statistics for 2022, around 6,700 Canadians were diagnosed with leukemia in 2021, out of which 4,000 were men and 2,700 were women. As per the American Cancer Society's data for 2023, around 59,610 new cases of leukemia and 20,380 new cases of acute myeloid leukemia (AML) are estimated to be diagnosed in the United States in 2023. Thus, the high incidence of cancer cases is leading to an increase in hemato oncology testing, thereby driving the market in the region.
According to an article published by the Heart and Stroke Foundation of Canada in February 2022, in Canada, 750,000 people were living with heart failure in 2022, and 100,000 people are diagnosed with this incurable condition each year. The source also stated that heart failure affects one in three Canadians, either because they have it themselves or because it affects a family member or close friend. Thus, the country's high burden of cardiovascular diseases is expected to boost the market's growth.
The rising developments by major market players are also expected to drive the market. For instance, in June 2021, the US FDA approved Pradaxa (dabigatran etexilate), an oral anticoagulant drug. The drug is used to treat children three months to under 12 years old with venous thromboembolism (a condition where blood clots form in the veins) directly after being treated with a blood thinner given by injection for at least five days.
Thus, factors such as the rising prevalence of cancer and other metabolic disorders and the rising developments by key market players are expected to drive the market in the region.
Peptide And Anticoagulant Drugs Industry Overview
The peptide and anticoagulant drugs market is highly competitive and consists of several major players. Some companies currently dominating the market are Amgen Inc., Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company, EVER Pharma, Johnson & Johnson, Pfizer Inc., Sanofi, Novartis AG, and Novo Nordisk AS.
Peptide And Anticoagulant Drugs Market Leaders
Amgen Inc.
Bayer AG
Boehringer Ingelheim International GmbH
Johnson & Johnson
Pfizer Inc.
*Disclaimer: Major Players sorted in no particular order
Peptide And Anticoagulant Drugs Market News
- In October 2022, Tiefeenbacher Pharmaceuticals launched the generic version of Apixaban for an early market entry in Canada. Apixaban is an oral anticoagulant (blood thinner) indicated for preventing venous thromboembolism (VTE) in adult patients.
- In February 2022, Bayer AG won fast-track status from the US FDA drug regulators for a new blood thinner designed to prevent certain types of strokes. The FDA granted fast-track designation for the review of drug candidate asundexian when tested to prevent a repeat in patients that suffered a non-cardioembolic stroke from clogged vessels.
Peptide & Anticoagulant Drugs Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Cancer and Metabolic Disorders
4.2.2 Rising Investments in R&D of Novel Drugs
4.2.3 Technological Advancements in Drug Development
4.3 Market Restraints
4.3.1 High Cost of Developing Drugs
4.3.2 Stringent Government Regulations
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Route of Administration
5.1.1 Peptide Drugs
5.1.1.1 Parenteral
5.1.1.2 Oral
5.1.1.3 Mucosal
5.1.1.4 Other Routes of Administration
5.1.2 Anticoagulant Drugs
5.1.2.1 Oral
5.1.2.2 Injectable
5.2 By Application
5.2.1 Peptide Drugs
5.2.1.1 Gastrointestinal Disorders
5.2.1.2 Neurological Disorders
5.2.1.3 Metabolic Disorders
5.2.1.4 Cancer
5.2.1.5 Other Applications
5.2.2 Anticoagulant Drugs
5.2.2.1 Atrial Fibrillation and Heart Attack
5.2.2.2 Stroke
5.2.2.3 Deep Vein Thrombosis (DVT)
5.2.2.4 Pulmonary Embolism (PE)
5.2.2.5 Other Applications
5.3 By Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Amgen Inc.
6.1.2 Bayer AG
6.1.3 Boehringer Ingelheim International GmbH
6.1.4 Bristol-Myers Squibb Company
6.1.5 Daiichi Sankyo Company
6.1.6 EVER Pharma
6.1.7 Johnson & Johnson
6.1.8 Pfizer Inc.
6.1.9 Sanofi
6.1.10 Novartis AG
6.1.11 Novo Nordisk AS
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Peptide And Anticoagulant Drugs Industry Segmentation
Anticoagulants, commonly known as blood thinners, are used to block and treat blood clots in blood vessels and the heart that can cause severe complications as the clot disrupts the flow of blood to essential organs and can result in heart attack and stroke. Peptides are long-chain amino acids that are held together by peptide bonds, also called amide bonds.
The peptide and anticoagulant drugs market is segmented by route of administration (peptide drugs (parenteral, oral, mucosal, and other routes of administration) and anticoagulant drugs (oral and injectable)), application (peptide drugs (gastrointestinal disorders, cardiovascular disorders, neurological disorders, metabolic disorders, cancer, and other applications) and anticoagulant drugs (atrial fibrillation and heart attack, stroke, deep vein thrombosis (DVT), pulmonary embolism (PE) and other applications)) and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers the value (in USD million) for the above segments.
| By Route of Administration | ||||||
| ||||||
|
| By Application | |||||||
| |||||||
|
| By Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Peptide & Anticoagulant Drugs Market Research FAQs
What is the current Peptide and Anticoagulant Drugs Market size?
The Peptide and Anticoagulant Drugs Market is projected to register a CAGR of 3.30% during the forecast period (2024-2029)
Who are the key players in Peptide and Anticoagulant Drugs Market?
Amgen Inc., Bayer AG , Boehringer Ingelheim International GmbH, Johnson & Johnson and Pfizer Inc. are the major companies operating in the Peptide and Anticoagulant Drugs Market.
Which is the fastest growing region in Peptide and Anticoagulant Drugs Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Peptide and Anticoagulant Drugs Market?
In 2024, the North America accounts for the largest market share in Peptide and Anticoagulant Drugs Market.
What years does this Peptide and Anticoagulant Drugs Market cover?
The report covers the Peptide and Anticoagulant Drugs Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Peptide and Anticoagulant Drugs Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Peptide and Anticoagulant Drugs Industry Report
Statistics for the 2024 Peptide And Anticoagulant Drugs market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Peptide And Anticoagulant Drugs analysis includes a market forecast outlook to for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
